Sangamo Therapeutics Inc (NASDAQ: SGMO)’s stock price has gone rise by 9.23 in comparison to its previous close of 0.71, however, the company has experienced a 7.27% increase in its stock price over the last five trading days. seekingalpha.com reported 2025-04-04 that Sangamo Therapeutics, Inc.’s deal with Eli Lilly to develop genomic medicines for CNS using the STAC-BBB AAV capsid brings in an $18M upfront payment and the potential to earn $1.4B in milestone payments. The Fabry Disease gene therapy program, with phase 1/2 STAAR study data expected in 1H 2025, is a major near-term catalyst for investors to keep an eye on. Positive eGFR slope data could lead to an Accelerated Approval filing of isaralgagene civaparvovec for Fabry Disease in the 2nd half of 2025.
Is It Worth Investing in Sangamo Therapeutics Inc (NASDAQ: SGMO) Right Now?
The stock has a 36-month beta value of 1.40. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 2 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for SGMO is 214.59M, and at present, short sellers hold a 11.89% of that float. On April 21, 2025, the average trading volume of SGMO was 6.60M shares.
SGMO’s Market Performance
SGMO’s stock has seen a 7.27% increase for the week, with a -8.15% drop in the past month and a -29.29% fall in the past quarter. The volatility ratio for the week is 8.14%, and the volatility levels for the past 30 days are at 13.62% for Sangamo Therapeutics Inc The simple moving average for the past 20 days is 6.19% for SGMO’s stock, with a -34.79% simple moving average for the past 200 days.
Analysts’ Opinion of SGMO
Many brokerage firms have already submitted their reports for SGMO stocks, with Truist repeating the rating for SGMO by listing it as a “Buy.” The predicted price for SGMO in the upcoming period, according to Truist is $7 based on the research report published on December 13, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see SGMO reach a price target of $10. The rating they have provided for SGMO stocks is “Buy” according to the report published on December 10th, 2024.
RBC Capital Mkts gave a rating of “Sector Perform” to SGMO, setting the target price at $2 in the report published on November 03rd of the previous year.
SGMO Trading at -13.98% from the 50-Day Moving Average
After a stumble in the market that brought SGMO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -75.76% of loss for the given period.
Volatility was left at 13.62%, however, over the last 30 days, the volatility rate increased by 8.14%, as shares sank -10.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.62% lower at present.
During the last 5 trading sessions, SGMO rose by +8.49%, which changed the moving average for the period of 200-days by +143.52% in comparison to the 20-day moving average, which settled at $0.7259. In addition, Sangamo Therapeutics Inc saw -24.44% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for SGMO
Current profitability levels for the company are sitting at:
- -1.69 for the present operating margin
- 0.91 for the gross margin
The net margin for Sangamo Therapeutics Inc stands at -1.69. The total capital return value is set at -1.75. Equity return is now at value -187.83, with -73.33 for asset returns.
Based on Sangamo Therapeutics Inc (SGMO), the company’s capital structure generated 0.57 points at debt to capital in total, while cash flow to debt ratio is standing at -2.2.
Currently, EBITDA for the company is -89.09 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of 2.72. The receivables turnover for the company is 12.57for trailing twelve months and the total asset turnover is 0.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.13.
Conclusion
To sum up, Sangamo Therapeutics Inc (SGMO) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
